Suzhou-based CStone Pharmaceuticals’ checkpoint inhibitor sugemalimab has proved effective in a trial as a first-line therapy for oesophageal cancer, setting up a regulatory filing in China.
EQRx – a focused on expanding access to innovative medicines – has announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has accepted a marketing authorisation application (MAA) for sugemalimab.
A Pfizer cancer drug partner in China is considering a sale as the biotech’s commercial path in the U.S. looks uncertain and competition in its home country intensifies. CStone Pharmaceuticals is exploring strategic options including a sale, Bloomberg reports, citing people familiar with the company.
A combination of EQRx and CStone’s PD-(L)1 drug sugemalimab and chemotherapy significantly prolonged patients’ lives over placebo in patients with newly diagnosed stage IV non-small cell lung cancer, according to updated data from the Phase III GEMSTONE-302 study unveiled Tuesday evening.